Edoxaban tosylate Monohydrate

Catalog No.S7280 Synonyms: DU-176b

For research use only.

Edoxaban (DU-176b) is a selective factor Xa inhibitor with Ki of 0.561 nM, >10 000-fold selectivity over thrombin and FIXa, and is also an orally bioavailable anticoagulant drug.

Edoxaban tosylate Monohydrate Chemical Structure

CAS No. 1229194-11-9

Selleck's Edoxaban tosylate Monohydrate has been cited by 6 Publications

Purity & Quality Control

Choose Selective Factor Xa Inhibitors

Other Factor Xa Products

Biological Activity

Description Edoxaban (DU-176b) is a selective factor Xa inhibitor with Ki of 0.561 nM, >10 000-fold selectivity over thrombin and FIXa, and is also an orally bioavailable anticoagulant drug.
Factor Xa [1]
(Cell-free assay)
0.561 nM(Ki)
In vitro

In human plasma, Edoxaban doubles prothrombin time and activates partial thromboplastin time at 0.256 and 0.508 μM, respectively. [1]

In vivo Oral administration of Edoxaban produces potent anti-Xa activity and high drug concentration in plasma in rats and monkeys. In vivo, Edoxaban dose-dependently inhibits thrombus formation in rat and rabbit thrombosis models. [1]

Protocol (from reference)

Animal Research:[1]
  • Animal Models: Venous stasis thrombosis model in rats and rabbits
  • Dosages: 0.3–3 mg/kg (Rabbit); 0.5–12.5 mg/kg (Rat)
  • Administration: p.o.
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 100 mg/mL
(135.45 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 738.27


CAS No. 1229194-11-9
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04747496 Recruiting Drug: Edoxaban Non-valvular Atrial Fibrillation Daiichi Sankyo Inc.|Daiichi Sankyo (China) Holdings Co. Ltd. February 26 2021 --
NCT04516941 Recruiting Drug: Edoxaban Tablets|Drug: Colchicine Tablets SARS-CoV Infection|COVID-19 University Hospital Inselspital Berne|Daiichi Sankyo Europe GmbH a Daiichi Sankyo Company January 21 2021 Phase 3
NCT04671316 Completed Drug: DA-5209 60mg Tab|Drug: Lixiana 60mg Tab Healthy Dong-A ST Co. Ltd. November 23 2020 Phase 1
NCT04597593 Recruiting -- Drug-Related Side Effects and Adverse Reactions|Iatrogenic Disorder Cipherome Inc.|Seoul National University Bundang Hospital October 7 2020 --
NCT04594915 Recruiting Drug: Edoxaban Atrial Fibrillation Daiichi Sankyo Turkey a Daiichi Sankyo Company|Daiichi Sankyo Inc. August 14 2020 --
NCT04072068 Recruiting Drug: Edoxaban Thromboembolism|Cancer Gruppo Oncologico Italiano di Ricerca Clinica June 27 2019 Phase 4

(data from https://clinicaltrials.gov, updated on 2021-09-06)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Edoxaban tosylate Monohydrate | Edoxaban tosylate Monohydrate supplier | purchase Edoxaban tosylate Monohydrate | Edoxaban tosylate Monohydrate cost | Edoxaban tosylate Monohydrate manufacturer | order Edoxaban tosylate Monohydrate | Edoxaban tosylate Monohydrate distributor